American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation.

Background: Survivin and livin are novel members of the inhibitor of apoptosis protein family, which have rarely been studied in human colorectal cancer (CRC). This study aims to examine their expression and association with clinicopathological factors and prognosis in CRC, and evaluate the possibility of their use as biomarkers for CRC. Patients and Methods: We investigated the expression of survivin and livin in 61 CRC samples using immunohistochemical staining (Envision) and correlated it with the survival of these patients using log-rank test and correlation analysis. Results: Among the 61 cases, 60.7 and 54.1% were positive for expression of survivin (p < 0.05) and livin (p < 0.05). No expression of survivin and livin was detected in normal colorectal mucosa. An inverse correlation (r = –0.9916) between the increased survivin and livin levels and overall survival was observed in univariate survival analysis. The expression of both proteins was not correlated with age, gender, degrees of differentiation, and TNM stage (p < 0.05) in malignancies. Conclusions: High expression of both survivin and livin may influence the prognosis of CRC. This finding opens new perspectives for CRC prognosis because survivin and livin can both be used as biomarkers or potential therapeutic targets.

No abstract